Abstract
Background Vast transcriptomics and epigenomics changes are characteristic of human cancers including leukemia. At remission, we assume that these changes normalise so that omics-profiles resemble those of healthy individuals. However, an in-depth transcriptomic and epigenomic analysis of cancer remission has not been undertaken. A striking exemplar of targeted remission induction occurs in chronic myeloid leukemia (CML) following tyrosine kinase inhibitor (TKI) therapy.
Methods Using RNA sequencing and whole-genome bisulfite sequencing, we profiled samples from chronic-phase CML patients at diagnosis and remission, and compared these to healthy donors.
Results Remarkably, our analyses revealed that abnormal splicing distinguishes remission samples from normal controls. This phenomenon is independent of the TKI drug used and in striking contrast to the normalisation of gene expression and DNA methylation patterns. Most remarkable are the high intron retention (IR) levels that even exceed those observed in the diagnosis samples. Increased IR affects cell cycle regulators at diagnosis and splicing regulators at remission. We show that aberrant splicing in CML is associated with reduced expression of specific splicing factors, histone modifications and reduced DNA methylation.
Conclusions Our results provide novel insights into the changing transcriptomic and epigenomic landscapes of CML patients during remission. The conceptually unanticipated observation of widespread aberrant alternative splicing after remission induction warrants further exploration. These results have broad implications for studying CML relapse and treating minimal residual disease.
Competing Interest Statement
S.B. is member of the advisory board of Qiagen, Novartis and Cepheid, received honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid, and research support from Novartis. D.W. received RS funding and honoraria from BMS and honoraria from Amgen. J.E.J.R. has received honoraria or speakers fees (GSK, Miltenyi, Takeda, Gilead, Pfizer, Spark, Novartis, Celgene, bluebird bio); Director of Pathology (Genea); equity ownership (Genea, Rarecyte); consultant (Rarecyte, Imago); chair, Gene Technology Technical Advisory, OGTR, Australian Government. The remaining authors declare no competing financial interests.
Funding Statement
This work was supported by the National Health and Medical Research Council (Investigator Grant #1177305 to J.E.J.R., Project #1128175 and #1129901 to J.E.J.R. and J.J.-L.W., #1126306 to J.J.-L.W., APP1027531 and APP1104425 to S.B., and APP1135949 to T.P.H.; the NSW Genomics Collaborative Grant (J.E.J.R. and J.J.-L.W.); Cure the Future (J.E.J.R.); and an anonymous foundation (J.E.J.R.). U.S. and J.J.-L.W. hold Fellowships from the Cancer Institute of New South Wales. U.S. also received support from the Australian Academy of Science in form of an Australia-India Early and Mid-Career Fellowship. Financial support was provided by Tour de Cure (Scott Canner Research Fellowship) to C.G.B. and for research grants to C.G.B. and J.E.J.R. This research was funded by the Cancer Council NSW Project Grants (RG11-12, RG14-09, RG20-12) to J.E.J.R., C.G.B., and U.S. Support was also received from the Ray and Shirl Norman Cancer Research Trust (S.B.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were approved by the institutional review boards (HREC protocol No: 131015, 070718c, 081211, and 101010 - Royal Adelaide Hospital) and are in accordance with the Declaration of Helsinki. Patients provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset supporting the conclusions of this article is available in the GEO repository, GSE144119.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144119
List of abbreviations
- CML
- chronic myeloid leukemia
- DEU
- Differential exon usage
- DUEs
- differentially used exons
- DMRs
- Differentially methylated regions
- FC
- fold change
- GO
- gene ontology
- IR
- intron retention
- PBMCs
- peripheral blood mononuclear cells
- Ph+
- Philadelphia-positive
- TCGA
- The Cancer Genome Atlas
- TPM
- transcripts per million
- TKI
- tyrosine kinase inhibitor
- WGBS
- Whole genome bisulfite sequencing
